EMG
PDLI

ETF Managers Group’s PDL BioPharma, Inc. PDLI Stock Holding History

ETF Managers Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-255,315
Closed -$733K – 640
2018
Q2 		$733K Buy
+255,315
New +$713K 0.05% 146
2018
Q1 		– Sell
-255,315
Closed -$733K – 573
2017
Q4 		$733K Buy
+255,315
New +$784K 0.05% 165

Other funds holding PDLI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

ETF Managers Group's PDLI Position: Q3 2018 in Review

ETF Managers Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 255,315 shares — an estimated $733K sold.

ETF Managers Group first reported a position in PDLI in Q4 2017 and held it in 2 quarters. The position peaked at $733K in Q2 2018. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

  • ETF Managers Group reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
  • ETF Managers Group sold 255,315 PDL BioPharma, Inc. shares in Q3 2018, an estimated $733K.
  • ETF Managers Group first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 2 quarters.
  • ETF Managers Group's PDL BioPharma, Inc. position peaked at $733K in Q2 2018.
  • 152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on ETF Managers Group's 13F filing for Q3 2018, filed 14 Nov 2018.